ID   OV1/CDDP
AC   CVCL_8745
DR   cancercelllines; CVCL_8745
DR   Wikidata; Q54936878
RX   PubMed=2731146;
RX   PubMed=17934650;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); ClinVar=VCV001756201; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1304 ! IGROV-1
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   PubMed=2731146; DOI=10.1016/0165-4608(89)90227-6;
RA   Teyssier J.-R., Benard J., Ferre D., Da Silva J., Bettan-Renaud L.;
RT   "Drug-related chromosomal changes in chemoresistant human ovarian
RT   carcinoma cells.";
RL   Cancer Genet. Cytogenet. 39:35-43(1989).
//
RX   PubMed=17934650; DOI=10.1590/S0100-879X2007001100014;
RA   Ait M'barek L., Ait Mouse H., Jaafari A., Aboufatima R., Benharref A.,
RA   Kamal M., Benard J., El Abbadi N., Bensalah M., Gamouh A., Chait A.,
RA   Dalal A., Zyad A.;
RT   "Cytotoxic effect of essential oil of thyme (Thymus broussonettii) on
RT   the IGR-OV1 tumor cells resistant to chemotherapy.";
RL   Braz. J. Med. Biol. Res. 40:1537-1544(2007).
//